Literature DB >> 15772203

Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.

M Jones1, P McEwan, C Ll Morgan, J R Peters, J Goodfellow, C J Currie.   

Abstract

OBJECTIVE: To evaluate how well patients with non-valvar atrial fibrillation (NVAF) were maintained within the recommended international normalised ratio (INR) target of 2.0-3.0 and to explore the relation between achieved INR control and clinical outcomes.
DESIGN: Record linkage study of routine activity records and INR measurements.
SETTING: Cardiff and the Vale of Glamorgan, South Wales, UK. PARTICIPANTS: 2223 patients with NVAF, no history of heart valve replacement, and with at least five INR measurements. MAIN OUTCOME MEASURES: Mortality, ischaemic stroke, all thromboembolic events, bleeding events, hospitalisation, and patterns of INR monitoring.
RESULTS: Patients treated with warfarin were outside the INR target range 32.1% of the time, with 15.4% INR values > 3.0 and 16.7% INR values < 2.0. However, the quartile with worst control spent 71.6% of their time out of target range compared with only 16.3% out of range in the best controlled quartile. The median period between INR tests was 16 days. Time spent outside the target range decreased as the duration of INR monitoring increased, from 52% in the first three months of monitoring to 30% after two years. A multivariate logistic regression model showed that a 10% increase in time out of range was associated with an increased risk of mortality (odds ratio (OR) 1.29, p < 0.001) and of an ischaemic stroke (OR 1.10, p = 0.006) and other thromboembolic events (OR 1.12, p < 0.001). The rate of hospitalisation was higher when INR was outside the target range.
CONCLUSIONS: Suboptimal anticoagulation was associated with poor clinical outcomes, even in a well controlled population. However, good control was difficult to achieve and maintain. New measures are needed to improve maintenance anticoagulation in patients with NVAF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15772203      PMCID: PMC1768813          DOI: 10.1136/hrt.2004.042465

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  22 in total

1.  Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists.

Authors:  B A Hutten; M H Prins; W K Redekop; J G Tijssen; S H Heisterkamp; H R Büller
Journal:  Thromb Haemost       Date:  1999-10       Impact factor: 5.249

2.  Recommendations for patients undertaking self management of oral anticoagulation.

Authors:  D A Fitzmaurice; S J Machin
Journal:  BMJ       Date:  2001-10-27

Review 3.  American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.

Authors:  Jack Hirsh; Valentin Fuster; Jack Ansell; Jonathan L Halperin
Journal:  Circulation       Date:  2003-04-01       Impact factor: 29.690

Review 4.  Antithrombotic therapy for atrial fibrillation.

Authors:  Gregory Y H Lip; Robert G Hart; Dwayne S G Conway
Journal:  BMJ       Date:  2002-11-02

5.  Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness.

Authors:  L Kalra; G Yu; I Perez; A Lakhani; N Donaldson
Journal:  BMJ       Date:  2000-05-06

Review 6.  Atrial fibrillation in the elderly: facts and management.

Authors:  Guy Chatap; Karine Giraud; Jean-Pierre Vincent
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 7.  Anticoagulants for atrial fibrillation: why is the treatment rate so low?

Authors:  Thomas A Buckingham; Robert Hatala
Journal:  Clin Cardiol       Date:  2002-10       Impact factor: 2.882

8.  Acetaminophen and other risk factors for excessive warfarin anticoagulation.

Authors:  E M Hylek; H Heiman; S J Skates; M A Sheehan; D E Singer
Journal:  JAMA       Date:  1998-03-04       Impact factor: 56.272

9.  Does the Birmingham model of oral anticoagulation management in primary care work outside trial conditions?

Authors:  D A Fitzmaurice; E T Murray; K M Gee; T F Allan
Journal:  Br J Gen Pract       Date:  2001-10       Impact factor: 5.386

10.  Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison.

Authors:  M E Cromheecke; M Levi; L P Colly; B J de Mol; M H Prins; B A Hutten; R Mak; K C Keyzers; H R Büller
Journal:  Lancet       Date:  2000-07-08       Impact factor: 79.321

View more
  82 in total

1.  [Persistent left atrial thrombus in atrial fibrillation under oral anticoagulation].

Authors:  B Leithäuser; F Kasch; T Broemel; J-W Park
Journal:  Herz       Date:  2010-12       Impact factor: 1.443

Review 2.  [Oral anticoagulation and risk of bleeding in elderly patients - the aspect of polypharmacy].

Authors:  Regina E Roller; Bernhard Iglseder; Peter Dovjak; Monika Lechleitner; Ulrike Sommeregger; Ursula Benvenuti-Falger; Ronald Otto; Birgit Böhmdorfer; Markus Gosch
Journal:  Wien Med Wochenschr       Date:  2010-06

3.  The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.

Authors:  Dorien Groenendaal; Gregory Strabach; Alberto Garcia-Hernandez; Takeshi Kadokura; Marten Heeringa; Roelof Mol; Charlotte Eltink; Hartmut Onkels
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

4.  Warfarin: almost 60 years old and still causing problems.

Authors:  Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-11       Impact factor: 4.335

5.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 6.  The future prospects of pharmacogenetics in oral anticoagulation therapy.

Authors:  Farhad Kamali; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

Review 7.  Drug adherence in patients taking oral anticoagulation therapy.

Authors:  Sebastian Ewen; Volker Rettig-Ewen; Felix Mahfoud; Michael Böhm; Ulrich Laufs
Journal:  Clin Res Cardiol       Date:  2013-09-03       Impact factor: 5.460

Review 8.  [Pharmacogenetics. Clinical relevance in anesthsiology].

Authors:  E M Zeidler; A E Goetz; C Zöllner
Journal:  Anaesthesist       Date:  2013-11       Impact factor: 1.041

9.  A Bayesian dose-individualization method for warfarin.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

10.  Novel anticoagulants in atrial fibrillation stroke prevention.

Authors:  Nicholas B Norgard; James J Dinicolantonio; Taylor J Topping; Benjamin Wee
Journal:  Ther Adv Chronic Dis       Date:  2012-05       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.